Articles published by Genexine, Inc.

Genexine’s GX-BP1 (SOX2 bioPROTAC) Suppresses Tumor Regrowth despite Osimertinib and Dato-DXd Combination and Achieves 6/6 Complete Responses in Triple Combination

September 15, 2026

From Genexine, Inc.

Via Business Wire

Genexine’s First-in-Class SOX2 Degrader GX-BP1 Demonstrates Up to 96% TGI and Eliminates Tumor Regrowth in Preclinical Models

April 28, 2026

From Genexine, Inc.

Via Business Wire

Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)

October 23, 2023

From Genexine, Inc.

Via Business Wire

Genexine’s long-acting growth hormone meets Phase 3 primary endpoint

August 30, 2023

From Genexine, Inc.

Via Business Wire

Genexine Abstract on GX-188E and GX-I7 Triple Combination Therapy in HNSCC Is Released at 2023 ASCO Annual Meeting

May 26, 2023

From Genexine, Inc.

Via Business Wire

Genexine’s Long-acting Anemia Treatment GX-E4 Phase 3 Clinical Trial Interim Result Is Presented at WCN2023, Confirmed Non-inferiority Compared to Mircera

April 11, 2023

From Genexine, Inc.

Via Business Wire

Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for its promising DNA vaccine for advanced cervical cancer

January 20, 2023

From Genexine, Inc.

Via Business Wire

Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congress 2022

August 25, 2022

From Genexine, Inc.

Via Business Wire

Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)

August 17, 2022

From Genexine, Inc.

Via Business Wire

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

June 14, 2022

From Genexine, Inc.

Via Business Wire

Genexine reports encouraging top-line results of the Phase 1b/2 clinical trial with GX-I7 (efineptakin alfa) in refractory or recurrent (R/R) metastatic Triple Negative Breast Cancer

June 07, 2022

From Genexine, Inc.

Via Business Wire

Genexine Appoints Industry Veteran Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

May 24, 2022

From Genexine, Inc.

Via Business Wire

Genexine to Present at H.C. Wainwright Global Investment Conference

May 24, 2022

From Genexine, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.